Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib in GEP-NET G3
NCT03457844Phase 2Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jan 2018
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib in gastroenteropancreatic neuroendocrine tumor (GEP-NET), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoint: Progression Free Survival up to 24 months. Status: unknown.
02
Drugs
anlotinib
03
Conditions
gastroenteropancreatic neuroendocrine tumor (GEP-NET)
Beyond the preview
Go deeper on NCT03457844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03457844.